yahoo_financeOriginal article
Roche’s collaborator MediLink announces phase III data for Tam-Peli showing significantly improved overall survival in Chinese patient population with relapsed small-cell lung cancer
Phase 3positiveTam-PeliPositive
AI Analysis
Summary
MediLink's Tam-Peli demonstrated significantly improved overall survival in Phase III trials for relapsed small-cell lung cancer in Chinese patients, with backing from Roche collaborator.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Outcome Details
significantly improved overall survival in Chinese patient population with relapsed small-cell lung cancer
Importance:7/10
Sentiment:
0.75
Phase 3 dataoncologysmall-cell lung cancerChinaoverall survivalcollaboration
Related Companies
Read the original article
Published by yahoo_finance on September 13, 2026 12:00 AM